Abbott to double down on Dx business; Hospital saves major money by eliminating unneeded cardiac biomarker testing;

> Abbott Laboratories ($ABT) is doubling down even more on its diagnostics and devices business, with plans to sell its generics portfolio for $5.3 billion. Story

> C2N Diagnostics has expanded its partnership with the Washington University School of Medicine in St. Louis focused on developing a blood test that spots Alzheimer's disease at its earliest stages. Release

> Transplant Genomics in Brookline, MA, said it has gained an exclusive license to patents co-owned by Northwestern University and the Scripps Research Institute that form the basis of diagnostic tests to improve how organ transplant patients are managed. Release

> An Ohio diagnostics laboratory is readying for new growth thanks to its iPad app that serves as a pathology reference tool. Story

> Researchers have developed a plasmonic chip for biomarker discovery and the diagnosis of Type 1 diabetes. Abstract

> A hospital said it saved $1.25 million in one year after eliminating unneeded cardiac biomarker testing for acute coronary syndrome. Story

Suggested Articles

J&J’s Ethicon unit received an FDA clearance for its Vistaseal applicators that spray a biologic sealant from Grifols to help stem surgical bleeding.

Bio-Techne’s urine test has received a breakthrough device designation from the FDA for ruling out unnecessary tissue biopsies.

Qiagen launched a one-stop shop compiling publicly available genomic data, scientific literature and phenotypic information on potential superbugs.